Web29 jun. 2024 · Jun. 29, 2024, 07:00 AM. BOSTON, June 29, 2024 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Tracy Palmer ... Web9 aug. 2024 · Ionis Pharmaceuticals kept its 2024 outlook intact Tuesday despite a broad …
Analyst Expectations for Ionis Pharmaceuticals
Web10 apr. 2024 · Ionis Pharmaceuticals, Inc. has a 12 month low of $31.46 and a 12 month high of $48.82. The stock has a market cap of $5.33 billion, a price-to-earnings ratio of -19.62 and a beta of 0.54. The company has a current ratio of 7.07, a quick ratio of 7.00 and a debt-to-equity ratio of 2.06. Ionis Pharmaceuticals ( NASDAQ:IONS - Get Rating) last ... WebIONIS PHARMACEUTICALS, INC. : Financial analyst guidance for IONIS PHARMACEUTICALS, INC. Stock Berne Stock Exchange: IONS Berne Stock Exchange first state to offer vote to women
Nick Afanasiev - Neuro Drug Discovery Scientist …
WebQuarterly Results – Agios Pharmaceuticals, Inc. Quarterly Results Year: 2024 2024 Q4 Q4 2024 Agios Pharmaceuticals Inc Earnings Conference Call Fourth Quarter 2024 Financial Results Presentation Agios Reports Fourth Quarter and Full Year 2024 Financial Results 10-K Annual Report Q3 Q3 2024 Agios Pharmaceuticals Inc Earnings Conference Call Web22 feb. 2024 · R&D revenue was higher in 2024 compared to 2024 primarily due to the $200 million Ionis earned in the fourth quarter of 2024 from AstraZeneca to jointly develop and commercialize eplontersen. Operating Expenses Web22 feb. 2024 · In October 2024, Ionis entered into a sale and leaseback transaction for several of its real estate assets. Under the agreement, Ionis received net proceeds of $200 million, with the potential to receive additional payments of up to $40 million plus … first state to make labor day a holiday